NeoX Biotech utilizes artificial intelligence and computational biophysics to develop macromolecular and multispecific drugs, focusing on immuno-oncology through the characterization of protein-protein interactions. The company collaborates with global biomedical firms to enhance the efficiency of early-stage drug discovery and development pipelines.
Funding
Funding not disclosed
Founders
Product
Problem
The early stages of drug discovery and development are often inefficient, particularly in the characterization of protein-protein interactions (PPIs) for macromolecular and multispecific drugs. Traditional methods can be time-consuming and may not fully capture the complexities of PPIs, hindering the development of effective therapeutics, especially in immuno-oncology.
Solution
NeoX Biotech leverages artificial intelligence (AI) and computational biophysics to enhance the early discovery of macromolecular and multispecific drugs, with a focus on immuno-oncology. The company has developed a platform that characterizes protein-protein interactions (PPIs) to accelerate drug research and development. By combining AI with biophysical techniques, NeoX Biotech aims to improve the efficiency of identifying and developing novel therapeutics. This approach enables the company to collaborate with global biomedical firms to optimize their drug R&D pipelines.
Target Audience
NeoX Biotech primarily serves global biomedical companies seeking to enhance the efficiency of their early-stage drug discovery and development pipelines.
Features
- AI-driven platform for characterizing protein-protein interactions (PPIs)
- Focus on macromolecular and multispecific drug development
- Application of computational biophysics in drug research
- Specialization in immuno-oncology therapeutics